172 related articles for article (PubMed ID: 35294647)
1. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of ARID1A negative expression in gastric cancer.
Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
6. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
[TBL] [Abstract][Full Text] [Related]
7. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
9. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
10.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
13.
Okamura R; Kato S; Lee S; Jimenez RE; Sicklick JK; Kurzrock R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111729
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.
Yang L; Wei S; Zhao R; Wu Y; Qiu H; Xiong H
Sci Rep; 2016 Jun; 6():28919. PubMed ID: 27354232
[TBL] [Abstract][Full Text] [Related]
17. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
18. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
19. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies.
Lee SY; Kim DW; Lee HS; Ihn MH; Oh HK; Park DJ; Kim HH; Kang SB
Oncology; 2015; 88(4):234-40. PubMed ID: 25503393
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.
Zhou Z; Huang D; Yang S; Liang J; Wang X; Rao Q
Pathol Oncol Res; 2022; 28():1610479. PubMed ID: 35928964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
